Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival

World Journal of Urology

Volumn 26, Issue 6, 2008, Pages 637-642

  Merseburger, Axel S ^a   Kramer, Mario W ^b   Hennenlotter, Jörg ^b   Serth, Jürgen ^a   Kruck, Stephan ^b   Gracia, Alfredo ^c   Stenzl, Arnulf ^b   Kuczyk, Markus A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Cedars Medical Center Miami   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Biomarker; Galectin 3; Prognosis; Renal cell cancer

Indexed keywords

GALECTIN 3; TUMOR MARKER;

ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

CARCINOMA, RENAL CELL; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 56449127154     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0294-8     Document Type: Article

References (21)

1. Jemal A et al (2006) Cancer statistics 2006. CA Cancer J Clin 56(2):106-130
2. Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169(3):821-827
3. Young AN et al (2001) Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158(5):1639-1651
4. Nakahara S, Raz A (2006) On the role of galectins in signal transduction. Methods Enzymol 417:273-289
5. Califice S et al (2004) Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23(45):7527-7536
6. van den Brule FA et al (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89(4):361-367
7. Cindolo L et al (1999) Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84(1):39-43
8. Francois C et al (1999) Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112(2):194-203
9. Merseburger AS et al (2005) Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25(3B):1901-1907
10. Merseburger AS et al (2006) Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma. Urologe A 45(3):323-327
11. Merseburger AS et al (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48(3):519-526
12. Kramer MW et al (2007) Tissue microarrays in clinical urology - technical considerations. Scand J Urol Nephrol 41(6):478-484
13. Ingrassia L et al (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13(29):3513-3527
14. Hahn HP et al (2004) Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 11(12):1277-1286
15. Rabinovich GA et al (2002) Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23(6):313-320
16. Castronovo V et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43-48
17. Choufani G et al (1999) The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86(11):2353-2363
18. Shimamura T et al (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8(8):2570-2575
19. Inohara H et al (1999) Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85(11):2475-2484
20. Hsu DK et al (1999) Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81(4):519-526
21. Lotan R et al (1994) Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56(4):474-480